Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and ...
Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage biopharma firm pioneering cannabis-based treatment to combat ...
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.40% to $18.78 Friday, on what proved to be an all-around great ...
Corbus Pharmaceuticals Holdings Inc. (CRBP) on Thursday reported a loss of $13.8 million in its third quarter. On a per-share basis, the ...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) has received an average recommendation of “Buy” from ...
NORWOOD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...
On Wednesday, B.Riley initiated coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and a price target of $85.00. The firm's coverage is based on the potential of... NORWOOD, MA ...
Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricted CB1 inverse agonist. The data are being ...
NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Thursday reported a loss of $13.8 million in its third quarter. On a per-share basis, the Norwood ...